The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.
IU School of Medicine
With more than 60 academic departments and specialty divisions across nine campuses and strong clinical partnerships with Indiana’s most advanced hospitals and physician networks, Indiana University School of Medicine is continuously advancing its miss...
Researchers from an Indiana University School of Medicine-led consortium of Alzheimer’s disease experts are studying how an anti-seizure drug used to treat epilepsy in children and adults could be repurposed as a potential therapeutic for Alzheimer’s disease.
Researchers at Indiana University School of Medicine are celebrating Federal Drug Administration approval of teplizumab, a new immunotherapy drug that delays the onset of type 1 diabetes in at-risk individuals by an average of almost three years.
Researchers from Indiana University School of Medicine have concluded the medical and scientific establishment should expand and re-contextualize its understanding of cannabis use and heart transplantation.
Most drugs developed to treat Alzheimer’s disease have for years been ineffective in clinical trials. Researchers from Indiana University School of Medicine recently evaluated the efficacy of a failed clinical trial drug using their rigorous pipeline.